Glaucoma

Pharmaceutical

Pharmaceutical Abstracts

2024 American Society of Cataract and Refractive Surgery

Overview of Switching from Latanoprost Alone or Adjunctive Therapy to Netarsudil/Latanoprost Fixed-Dose Combination for More IOP Lowering 

 

The Impact of Switching Patients on Latanoprost Monotherapy to Netarsudil/Latanoprost Fixed-Dose Combination for Additional IOP Reduction

 

Consolidating Drops: Switching from Latanoprost-Based Adjunctive Therapies to Netarsudil/Latanoprost Fixed-Dose Combination to Lower IOP 

 

Patient-Reported Outcomes and Investigator Impressions after Switching to Netarsudil/Latanoprost Fixed-Dose Combination Therapy

Pharmaceutical Posters

2023 American Academy of Optometry

Efficacy of Netarsudil 0.02% in Lowering Intraocular Pressure in Black Patients: Post Hoc Analysis of Pooled Phase 3 ROCKET Studies 

 

Efficacy of Netarsudil 0.02% Monotherapy and Netarsudil/Latanoprost 0.02%/0.005% Fixed Dose Combination in Lowering Intraocular Pressure in Black Patients: Post Hoc Analysis of Phase 3 MERCURY Data

 

Efficacy of Switching Patients with Uncontrolled IOP on Latanoprost Monotherapy to Netarsudil 0.02% Monotherapy and Netarsudil/Latanoprost 0.02%/0.005% Fixed Dose Combination

Clinical Trials

Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure

 

Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution Rho Kinase Elevated IOP Treatment Trial

 

Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure Randomized Phase 3 ROCKET 4 Study

 

Once-Daily Netarsudil-Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study

 

Netarsudil-Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial

 

Three-Month Randomized Trial of Fixed-Combination Brinzolamide, 1%, and Brimonidine, 0.2%

 

Phase 3 Randomized 3-Month Trial with an Ongoing 3-Month Safety Extension of Fixed Combination Brinzolamide 1%/Brimonidine, 0.2%

RHOPRESSA® (netarsudil ophthalmic solution) 0.02%

RHOPRESSA® s a prescription medicine to reduce high eye pressure (intraocular pressure, or IOP) in patients with open-angle glaucoma or ocular hypertension

View Full Prescribing Information Here

ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

ROCKLATAN® is a combination of two prescription medicines to reduce high eye pressure (intraocular pressure, or IOP) in patients with open-angle glaucoma or ocular hypertension

View Full Prescribing Information Here

SIMBRINZA® (brinzolamide and brimonidine tartrate ophthalmic suspension) 1%/0.2%

SIMBRINZA® is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

View Full Prescribing Information Here

You are on a website for Health Care Professionals in the United States

By clicking below “OK” you acknowledge that this site is intended for Health Care professionals only
OK Other country
© 2024 Alcon Inc. p-MED-US-EYS-240001